Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Non Alcoholic Fatty Liver Disease (NAFLD) Overview
  3. Therapeutics Development
  4. Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
  5. Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis
  6. Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies
  7. Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes
  8. Non Alcoholic Fatty Liver Disease (NAFLD) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies
  13. Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes
  14. Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
  • Arisaph Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Betagenon AB
  • Can-Fite BioPharma Ltd.
  • Conatus Pharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • Kyorin Pharmaceutical Co., Ltd.
  • Novartis AG
  • Sancilio & Company, Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

For more information visit http://www.researchandmarkets.com/research/fs79zn/non_alcoholic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716